Equity / Investment · CIS & Central Asia · Announced 23 Feb 2026
Kazakhstan Ministry of Health → Polpharma Santo
Polpharma Santo (Khimpharm) signed a KZT 39.5 billion (about US$79.5 million) investment agreement with Kazakhstan's Ministry of Health to expand its Shymkent plant and localize 38 products, including oncology and TB drugs.
Parties: Kazakhstan Ministry of Health (Kazakhstan) → Polpharma Santo (Khimpharm) (Kazakhstan)
- Deal type
- Equity / Investment
- Value
- $79.5m
- Territory
- Kazakhstan – Shymkent; export potential up to US$100 million
- Therapeutic area
- Multi-therapy
- Asset
- Shymkent plant expansion – 38 products
- Announced
- 23 Feb 2026
Our analysis
Why this matters
Polpharma Santo and Kazakhstan's Ministry of Health signed an investment agreement on 23 February 2026, under a government decision, to expand production at the company's plant in Shymkent. The investment is KZT 39.5 billion (about US$79.5 million), including KZT 10 billion for R&D and certification. The project covers 38 socially significant medicines for oncology, cardiovascular, infectious and chronic diseases and tuberculosis, produced to EU and EAEU GMP standards. It runs from 2026 to 2036, with construction starting in 2027 and the first phase due by the end of 2029, creating at least 300 jobs.
The company targets export potential of up to US$100 million and plans for at least half of output to go abroad by 2050. On 2–3 November 2026 the Ministry listed Khimpharm among eight signed pharma investment contracts totalling KZT 391.3 billion.
The full analysis is free to read with a work email on this page.
Source: PharmReviews.kz